Who Paid My Doc
David Gonzalez
Cardiovascular Disease Afton, WY Medical Doctor
NPI 1043208218 CMS profile 1104750
110 Hospital Ln, Afton, WY 83110
General payments
$6,049
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, David Gonzalez of Afton, WY is reported in the CMS Open Payments database as having received $6,049 across 218 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 73rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,465 | 65 | |
| 2024 | General | $754 | 44 | |
| 2023 | General | $581 | 40 | |
| 2022 | General | $870 | 19 | |
| 2021 | General | $435 | 16 | |
| 2020 | General | $269 | 14 | |
| 2019 | General | $675 | 20 |
Beside peers
- David Gonzalez
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to David Gonzalez were reported at $2,465. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | David Gonzalez | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $675 | $450 | $127–$1,392 | $163 |
| 2020 | $269 | $242 | $77–$751 | $114 |
| 2021 | $435 | $335 | $101–$1,037 | $132 |
| 2022 | $870 | $395 | $121–$1,211 | $149 |
| 2023 | $581 | $443 | $136–$1,283 | $160 |
| 2024 | $754 | $450 | $136–$1,323 | $164 |
| 2025 | $2,465 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 26 drugsPart D claims
864
Drug cost
$221,859
Branded share of claims
41.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 101 | $111,672 | |
| Entresto Sacubitril/Valsartan | Brand | 33 | $32,624 | |
| Xarelto Rivaroxaban | Brand | 29 | $25,666 | |
| Jardiance Empagliflozin | Brand | 26 | $21,674 | |
| Farxiga Dapagliflozin Propanediol | Brand | 14 | $12,008 | |
| Repatha Sureclick Evolocumab | Brand | 14 | $7,465 | |
| Dabigatran Etexilate Dabigatran Etexilate Mesylate | Brand | 12 | $1,928 | |
| Nitroglycerin | Generic | 25 | $1,184 | |
| Metoprolol Succinate | Generic | 77 | $1,016 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 55 | $1,015 |
The 10 drugs with the highest cost, of 26 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 13 billing codesPaid by Medicare
$5,324
Medicare patients
33
Services billed
49
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 55% | |
| Heart failure | 52% | |
| Arthritis | 45% | |
| Depression | 33% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VYNDAQEL |
|
$72 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
218 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Wyoming
Michel Skaf
Cardiovascular Disease · Casper, WY
Brian Kelly
Cardiovascular Disease · Powell, WY
Robert Novick
Cardiovascular Disease · Casper, WY
Adrian Fluture
Cardiovascular Disease · Casper, WY
Smitha Neerukonda
Cardiovascular Disease · Cheyenne, WY
Michael Brennan
Cardiovascular Disease · Sheridan, WY
Related records
Cardiovascular Disease in Wyoming
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Wyoming
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.